Wright Lassiter III - 01 Oct 2025 Form 4 Insider Report for QUEST DIAGNOSTICS INC (DGX)

Reporting relationship: Director
Issuer ticker: DGX
Reported as of: 01 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Oct 2025, 16:32:18 UTC
Prior SEC filing: 25 Jul 2025
Next SEC filing: 30 Dec 2025
Source filing: View source filing
Reporting owner signature: Sean D. Mersten, Attorney in Fact for Wright L. Lassiter, III

Key filing fact

Wright Lassiter III filed Form 4 for QUEST DIAGNOSTICS INC (DGX) on 03 Oct 2025.

Key facts

This page summarizes Wright Lassiter III's Form 4 filing for QUEST DIAGNOSTICS INC (DGX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Oct 2025, 16:32.

Change

Previous filing in this sequence was filed on 25 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001805909 Primary reporting owner

Lassiter Wright III

Relationship: Director
Address: 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS
Signature: Sean D. Mersten, Attorney in Fact for Wright L. Lassiter, III
Signature date: 03 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DGX transaction Derivative

Phantom Stock Units

Award

Transaction value: $0
Shares: +157
Change %: +30%
Price: $0.000000
Shares after: 679
Date: 01 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 157
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director.

Footnote F2

Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11.